Platelet phosphodiesterase inhibitors

Mechanism of antiplatelet action

The main task of dipyridamole is to prevent platelet aggregation. Its primary working principle consists in increasing the level of cyclic adenosine monophosphate (cAMP) inside blood plates. As a consequence of increased cAMP, the concentration of calcium ions ($Ca^{2+}$) in the cytoplasm drops sharply. Without calcium, the aggregation process is blocked, partly due to the inactivation of key receptors — glycoproteins GP IIb/IIIa.

This effect is realized through three main pathways:

1. Phosphodiesterase (PDE) inhibition: the drug directly blocks the enzyme that normally destroys cAMP, thereby promoting its intracellular accumulation.
2. Adenosine uptake blockade: dipyridamole prevents the absorption of adenosine by erythrocytes and endothelial cells. As a result, adenosine remains in the blood plasma.
3. Inhibition of adenosine metabolism: the drug inhibits the enzyme adenosine deaminase, protecting adenosine from degradation.

Adenosine pathway and influence on mediators

The accumulation of adenosine in the blood is a crucial stage of pharmacodynamics. Free adenosine actively stimulates $A_2$ receptors located on the platelet membrane. Activation of these receptors triggers the work of the enzyme adenylyl cyclase, which ultimately leads to powerful cAMP synthesis.

In addition, dipyridamole interferes with the work of other enzymes and mediators:

• Inhibition of thromboxane synthase: the synthesis of thromboxane $A_2$, which is one of the most powerful aggregation inducers, is suppressed.
• Stimulation of prostacyclin: the drug forces endothelial cells to release prostacyclin more actively, which is a natural factor preventing blood clotting.
• Vascular effect: the increase in cAMP levels occurs not only in platelets, but also in vascular smooth muscle cells. This causes their relaxation and leads to vasodilation (vasodilating effect).

Clinical use and combinations

Historically, dipyridamole was developed as a coronary vasodilator, but today its main role is the prevention of thrombosis. Due to its relatively weak intrinsic antiplatelet effect, it is extremely rarely used as monotherapy. It is prescribed as part of combination regimens:

• Peripheral arterial disease and prevention of ischemic stroke: used in strict combination with acetylsalicylic acid (ASA) for the mutual enhancement of the antithrombotic effect.
• Heart valve replacement: the drug is necessary to prevent thrombus formation on mechanical valves. In this situation, it is prescribed together with oral anticoagulants (for example, warfarin).

Dosing regimen and pH dependency

The method of administration of dipyridamole directly depends on its dosage form, since the absorption of the drug in the gastrointestinal tract critically depends on the acidity of the medium (pH).

• Standard form: prescribed 3–4 times a day. It is extremely important to take the tablets on an empty stomach (1 hour before meals) to ensure optimal absorption.
• Prolonged-release form (sustained-release): taken twice a day, and in this case, intake is preferable precisely during meals.

Drug interaction: the absorption of dipyridamole decreases sharply with an increase in gastric pH. Therefore, simultaneous administration with antisecretory drugs (proton pump inhibitors, $H_2$ antihistamine blockers) is strictly not recommended — they impair the bioavailability of the antiplatelet agent.

Safety profile and adverse effects

The comparative risk of bleeding events with dipyridamole is lower than with acetylsalicylic acid therapy. However, adverse reactions still occur and are caused by both systemic and vascular action:

• Cardiovascular system and central nervous system: due to vasodilation, arterial hypotension, dizziness, and headache are possible.
• Gastrointestinal tract: dyspeptic phenomena, including nausea and discomfort.
• Allergic reactions: skin manifestations (rash).

Key contraindication: stable angina pectoris. The mechanism of this risk is associated with the potential development of the "steal syndrome" (steal syndrome), which can critically worsen myocardial ischemia.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• The role of adenosine and $A_2$ receptors in platelet physiology
• Mechanism of inactivation of GP IIb/IIIa glycoproteins during intracellular calcium reduction
• Interaction of dipyridamole with oral anticoagulants (warfarin)
• Pharmacokinetics of prolonged-release forms of dipyridamole
• Pathophysiology of the "steal syndrome" in the coronary bed

Other topics in the section "Drugs affecting hemostasis and thrombosis"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.